Compare BridgeBio Pharma Inc (BBIO) vs Invesco DB Commodity Index Tracking Fund (DBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Invesco DB Commodity Index Tracking Fund — how do they compare? BridgeBio Pharma Inc trades at $84.61 (market cap $16.36B), while Invesco DB Commodity Index Tracking Fund trades at $30.05. Which is the better fit depends on your goals.
| BBIO | DBC | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $90.17 | $31.69 |
52-Week Low | $47.29 | $21.62 |
Enterprise Value | $18.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
DBC trades at $30.00, up 0.23% with a bullish technical signal from moving averages. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights commodities ETFs as inflation hedges, with articles discussing portfolio strategies and geopolitical impacts on commodity markets.
The outlook is cautiously optimistic due to technical strength, but lack of fundamental data poses risks. Opportunities include commodity exposure for diversification, while risks involve market volatility and reliance on broader commodity trends without company-specific financial clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →
